Ophthalmic ciclosporin nano-micelle medicine as well as preparation method and application thereof

Through nanomicellulose technology, a stable cyclosporine nanomicellulose is formed by combining specific solubilizers, which solves the problems of insufficient concentration and high irritation of cyclosporine eye drops, and achieves efficient and stable delivery of ocular drugs. Improves treatment effect and patient comfort.

CN118903006APending Publication Date: 2024-11-08THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

Patent Information

Application Number
CN202411301353.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing cyclosporine eye drops have problems of insufficient concentration and high local irritation in ophthalmic applications, and it is difficult to effectively increase the concentration of eye drugs to achieve better therapeutic effects.

Method used

Using nanomicellulose technology, a stable cyclosporine nanomicellulose is formed by combining a specific type of first solubilizer and second solubilizer. The direct hydration method is used to prepare high concentrations of cyclosporine eye drops to avoid using Organic solvents to improve the solubility and stability of drugs.

Benefits of technology

It realizes the high concentration accumulation of cyclosporine in the eye tissue, plays a rapid role, reduces local irritation, improves patient comfort and compliance, and the preparation process is simple and convenient, suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903006A_ABST
    Figure CN118903006A_ABST
Patent Text Reader

Abstract

The invention relates to an ophthalmic ciclosporin nano-micelle drug as well as a preparation method and application thereof. The ophthalmic ciclosporin nano-micelle drug is prepared from a first solubilizer, a second solubilizer and ciclosporin, wherein the first solubilizer and the second solubilizer form micelle particles, and the ciclosporin is loaded in the micelle particles. The first solubilizer and the second solubilizer which are of specific types and low in total cost are creatively compounded, the problem of solubility of cyclosporine in water is solved by means of the nano-micelle technology, cyclosporine can stably exist in an aqueous solution at a high concentration, higher-concentration accumulation of cyclosporine in eye tissues is facilitated, and the eye drops can be effectively absorbed. The local irritation is low. The ophthalmic ciclosporin nano-micelle medicine is prepared by adopting a direct hydration method which is different from a film hydration method for preparing most polymer micelles and the like, and the method does not use any organic solvent, is beneficial to industrial enlarged production, and is safe and environment-friendly.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to an ophthalmic cyclosporine nano-micelle drug and a preparation method and application thereof. Background Art

[0002] Cyclosporine, also known as cyclosporine A, is a cyclic polypeptide composed of 11 amino acids and is a potent and selective immunosuppressant. In recent years, cyclosporine has been used in ophthalmology to treat dry eye (keratoconjunctivitis sicca), keratoconjunctivitis and immune rejection after corneal transplantation. Its mechanism of action includes inhibiting T cell activation, thereby reducing the production of inflammatory cytokines, resisting cell apoptosis, increasing goblet cell density and mucin secretion levels, and increasing tear flow. Cyclosporine is safe and effective as a long-term clinical medication, has no systemic adverse reactions, and can significantly improve the discomfort symptoms of dry eye, keratoconjunctivitis and related eye diseases.

[0003] Cyclosporine is a highly lipid-soluble drug in the form of white powder. It is easily soluble in organic solvents such as acetonitrile and ethanol, and its water solubility in water is only 12ng / mL (25°C). However, when administered in the form of eye drops, the conjunctival sac volume of each eye usually does not exceed 30μL. Therefore, increasing the concentration of cyclosporine to increase the effective amount of drug acting on the eye and increasing the drug concentration in the eye tissue to achieve better effects are urgent research directions.

[0004] Currently, there are many cyclosporine preparations on the market, but most of them are oils or emulsions. Oils and emulsions usually have a strong burning sensation and irritation when used topically on the eyes. Therefore, it is urgent to develop new safe, effective and stable high-concentration cyclosporine eye drops. Summary of the invention

[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide an ophthalmic cyclosporine nano-micelle drug and a preparation method and application thereof, and specifically to provide an ophthalmic cyclosporine nano-micelle drug and a preparation method thereof and a cyclosporine eye drop and a preparation method thereof. The present invention utilizes nano-micelle technology to prepare a high-concentration stable ophthalmic solution preparation of the poorly soluble drug cyclosporine, which does not contain any oil phase component, has low irritation, and has a simple and convenient preparation process, and is easy to scale up and apply.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides an ophthalmic cyclosporine nano-micelle drug, which is composed of a first solubilizing agent and a second solubilizing agent that form micelle particles, and cyclosporine loaded in the micelle particles;

[0008] The first solubilizing agent is selected from any one or a combination of at least two of polyoxyethylene hydrogenated castor oil, polysorbate 80, lauryl alcohol polyoxyethylene ether (Brij35), poloxamer 188, polyoxyl 40 stearate or tyloxapol;

[0009] The second solubilizing agent is selected from polyethylene glycol 15-hydroxystearate or any one or a combination of at least two of the following structural compounds:

[0010]

[0011]

[0012] In the above structural compounds, R is independently selected from C9-C26 alkyl; R 1 Selected from C1-C5 alkylene; R 2 Each independently selected from H, methyl or ethyl; M+ is selected from Na + , K + or NH 4 + ; The molecular weight of the polyethylene glycol chain segments is independently 500-20000.

[0013] The C9-C26 alkyl group refers to C9 alkyl, C10 alkyl, C11 alkyl, C12 alkyl, C13 alkyl, C14 alkyl, C15 alkyl, C16 alkyl, C17 alkyl, C18 alkyl, C19 alkyl, C20 alkyl, C21 alkyl, C22 alkyl, C23 alkyl, C24 alkyl, C25 alkyl, C26 alkyl. The C1-C5 alkylene group refers to C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene.

[0014] The molecular weight of the polyethylene glycol chain segment can be independently selected to be 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 10000, 13000, 15000, 20000, etc. Other specific points within this numerical range can be selected and will not be described in detail here.

[0015] The ophthalmic cyclosporine nano-micelle drug of the present invention selects the first solubilizing agent and the second solubilizing agent of the specific type as described above, and solves the solubility problem of cyclosporine in water by means of nano-micelle technology, so that cyclosporine can be stably present in the aqueous solution at a higher concentration, which is conducive to the accumulation of a higher concentration of cyclosporine in the eye tissue, thereby facilitating the cyclosporine to take effect faster. In addition, the local irritation is low, which can improve the comfort of patients.

[0016] Cyclosporine cannot be successfully loaded with any solubilizer to form a stable micelle system. The first solubilizer used in the present invention belongs to a solubilizer commonly used in ophthalmic drugs, has a low price and good safety, but the first solubilizer solution alone cannot directly dissolve cyclosporine; the present invention creatively compounded the second solubilizer with the first solubilizer, and this combination method can make cyclosporine directly dissolve, and the direct hydration method can be used to prepare stable nano micelles with high cyclosporine content, which is simple, convenient, safe and environmentally friendly. The use of two solubilizers is not a simple superposition of the solubility of the two solubilizers. They affect each other and synergistically increase the solubility of cyclosporine, and the total cost is low, which has a high practical value.

[0017] Preferably, the second solubilizing agent is selected from polyethylene glycol 15-hydroxystearate, mPEG-DSPE (methoxy-polyethylene glycol-phosphatidylethanolamine), mPEG-DPPE (methoxy-polyethylene glycol-dipalmitoylphosphatidylethanolamine), ALC-0159 (methoxy polyethylene glycol ditetradecyl acetamide), mPEG-DMG (1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol), mPEG-DSG (methoxypolyethylene glycol dimethoxy-1,2-di ... any one or a combination of at least two of diol disuccinimidyl glutarate); in the above-mentioned structural compound, the molecular weight of the polyethylene glycol segment is independently 500-20000, for example, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 10000, 13000, 15000, 20000, etc., and other specific point values ​​within the numerical range can be selected, which will not be repeated here one by one.

[0018] Preferably, the ratio of the total mass of the first solubilizer and the second solubilizer to the mass of cyclosporine is not less than 4:1, for example 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, 7.5:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described one by one here.

[0019] Preferably, the mass ratio of the first solubilizer to the second solubilizer is not higher than 10:1, for example 9.5:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.5:1, 0.1:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0020] Preferably, the particle size of the ophthalmic cyclosporine nano-micelle drug is 5-100 nm, for example, 5 nm, 10 nm, 15 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, etc. Other specific point values ​​within this numerical range can be selected, which will not be described one by one here.

[0021] In a second aspect, the present invention provides a method for preparing the ophthalmic cyclosporine nano-micelle drug according to the first aspect, the preparation method comprising:

[0022] Cyclosporine is mixed with the first solubilizing agent, the second solubilizing agent and water to dissolve the cyclosporine, thereby obtaining the ophthalmic cyclosporine nano-micelle drug.

[0023] The ophthalmic cyclosporine nano-micelle drug involved in the present invention can be prepared by a direct hydration method, and cyclosporine can be completely dissolved within 4 hours. Different from the thin film hydration method and other methods for preparing most polymer micelles, this method is simple and convenient, does not use any organic solvent, is conducive to industrialized production, and is safe and environmentally friendly. The ophthalmic cyclosporine nano-micelle drug system prepared is very stable, has a long shelf life, and is conducive to storage and transportation.

[0024] Preferably, the dissolution is carried out at 0-70°C, for example, 2°C, 4°C, 10°C, 25°C, 30°C, 35°C, 40°C, 50°C, 60°C, 70°C, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0025] The above preparation method has no special requirement on temperature, and the product can be prepared at 0-70°C.

[0026] Preferably, the dissolution is carried out by any one or at least two of the following methods:

[0027] (1) Stirring; (2) Oscillation; (3) Ultrasonic treatment.

[0028] Preferably, the final concentration of cyclosporine in the mixed system is 0.2-10 mg / mL, for example, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, etc.

[0029] Preferably, the final concentration of the first solubilizer in the mixed system is 0.01-20 mg / mL, for example 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 5 mg / mL, 8 mg / mL, 10 mg / mL, 12 mg / mL, 14 mg / mL, 16 mg / mL, 18 mg / mL and the like.

[0030] Preferably, the final concentration of the second solubilizer in the mixed system is 2-30 mg / mL, for example 5 mg / mL, 8 mg / mL, 10 mg / mL, 12 mg / mL, 15 mg / mL, 18 mg / mL, 20 mg / mL, 22 mg / mL, 25 mg / mL, 28 mg / mL, 30 mg / mL and the like.

[0031] Other specific point values ​​within the above numerical range can be selected and will not be described in detail here.

[0032] Preferably, the ratio of the total mass of the first solubilizer and the second solubilizer to the mass of cyclosporine is not less than 4:1, for example 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, 7.5:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described one by one here.

[0033] Preferably, the mass ratio of the first solubilizer to the second solubilizer is not higher than 10:1, for example 9.5:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.5:1, 0.1:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0034] In a third aspect, the present invention provides use of the ophthalmic cyclosporine nano-micelle drug according to the first aspect in the preparation of an ophthalmic cyclosporine preparation.

[0035] In a fourth aspect, the present invention provides a cyclosporine eye drops, wherein the raw materials for preparing the cyclosporine eye drops include the ophthalmic cyclosporine nano-micelle drug according to the first aspect.

[0036] Preferably, the raw materials for preparing the cyclosporine eye drops further include any one of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative, or a combination of at least two of them.

[0037] In a fifth aspect, the present invention provides a method for preparing the cyclosporine eye drops according to the fourth aspect, the preparation method comprising:

[0038] The ophthalmic cyclosporine nano-micelle drug is prepared by mixing any one of an osmotic pressure regulator, a pH regulator, a thickener and a preservative or a combination of at least two of the osmotic pressure regulator, a pH regulator, a thickener and a preservative with the cyclosporine nano-micelle drug and dissolving them in water.

[0039] Preferably, after the mixed dissolution, the solution is filtered through a 0.22 micron filter to remove insoluble particles.

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] The ophthalmic cyclosporine nano-micelle drug involved in the present invention creatively compounds a first solubilizing agent and a second solubilizing agent of a specific type with a low total cost, and solves the solubility problem of cyclosporine in water by means of nano-micelle technology, so that cyclosporine can be stably present in an aqueous solution at a higher concentration, which is conducive to the accumulation of a higher concentration of cyclosporine in ocular tissues, thereby being conducive to cyclosporine taking effect faster. And the local irritation is low, which can improve the compliance and tolerance of patients. The product has good stability and is conducive to storage and transportation. And the ophthalmic cyclosporine nano-micelle drug is prepared by a direct hydration method, and cyclosporine can be completely dissolved within 4 hours. Different from the thin film hydration method for preparing most polymer micelles, the method does not use any organic solvent, is conducive to industrialized amplification production, and is safe and environmentally friendly. The total production cost of the method is low, and has great practical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 It is a graph showing the change of cyclosporine concentration in the bulbar conjunctiva over time after use of the eye drop product of the present invention and the control product;

[0043] Figure 2 It is a graph showing the change of cyclosporine concentration in the cornea over time after using the eye drop product of the present invention and the control product;

[0044] Figure 3 The figure is a graph showing the change of cyclosporine concentration in the sclera over time after use of the eye drop product involved in the present invention and the control product. DETAILED DESCRIPTION

[0045] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0046] The cyclosporine involved in the following content was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; polyoxyethylene hydrogenated castor oil was purchased from BASF; polysorbate 80 was purchased from Jiangxi Yipsheng Pharmaceutical Co., Ltd.; lauryl polyoxyethylene ether was purchased from Sigma-Aldrich; polyethylene glycol 15-hydroxystearate was purchased from BASF; stearic acid polyoxyl 40 ester was purchased from Beijing Puxitang Biotechnology Co., Ltd.; mPEG2000-DSPE was purchased from Jiangsu Southeast Nano Co., Ltd.; mPEG5000-DPPE was purchased from Aladdin Reagent (Shanghai) Co., Ltd.; ALC-0159 was purchased from Meiluo Technology Co., Ltd.; mPEG2000-DMG was purchased from MedChemExpress; mPEG2000-DSG was purchased from MedChemExpress; PVP-K90 was purchased from Boai New Open Source Medical Technology Group Co., Ltd.; and hydroxypropyl methylcellulose (labeled viscosity 4000) was purchased from Tai'an Ruitai Cellulose Co., Ltd.

[0047] The instruments used in the following contents include: laser particle size analyzer (Malvern, zetasizer ZSP); high performance liquid chromatograph (Shimadzu LC-20-AT); high performance liquid chromatography-mass spectrometry (Shimadzu LCMS8050); other reagents or instruments not specified are conventional products that can be purchased commercially.

[0048] The cyclosporine content was measured by the external standard method. The sample was centrifuged to obtain the supernatant before detection. The conditions for high performance liquid chromatography detection were: Agilent Zorbax C18 column, 5 μm, 4.6×250 mm, flow rate 1.0 mL / min, column temperature 70° C., detection wavelength 210 nm, injection volume 20 μL. The mobile phase was water: acetonitrile: tert-butyl methyl ether: phosphoric acid solution (85%) = 1040: 860: 100: 2 (volume ratio), isocratic elution.

[0049] Example 1

[0050] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0051] (1) Accurately weigh polyoxyethylene hydrogenated castor oil, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh MPEG-2000-DSPE, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0052] (2) Take 2 mL of MPEG-2000-DSPE solution, 3 mL of polyoxyethylene hydrogenated castor oil solution and 2 mL of purified water, mix them evenly, add 10 mg of cyclosporine, and continue stirring at 60° C. until the cyclosporine is dissolved.

[0053] Example 2

[0054] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0055] (1) Accurately weigh polyoxyethylene hydrogenated castor oil, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh MPEG-2000-DSPE, add pure water to dissolve, and prepare a 40 mg / mL solution.

[0056] (2) Take 2 mL of MPEG-2000-DSPE solution and mix evenly with 5 mL of polyoxyethylene hydrogenated castor oil solution, add 20 mg of cyclosporine, and continue stirring at 25° C. until the cyclosporine is dissolved.

[0057] Example 3

[0058] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0059] (1) Accurately weigh polysorbate 80, add pure water to dissolve it, and prepare a 20 mg / mL solution; accurately weigh MPEG-2000-DSPE, add pure water to dissolve it, and prepare a 20 mg / mL solution.

[0060] (2) Take 2 mL of MPEG-2000-DSPE solution, 3 mL of polysorbate 80 solution and 2 mL of purified water, mix them evenly, add 10 mg of cyclosporine, and continue stirring at 4°C until the cyclosporine is dissolved.

[0061] Example 4

[0062] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0063] (1) Accurately weigh polyoxyethylene hydrogenated castor oil, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh MPEG-2000-DMG, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0064] (2) Take 2.25 mL of MPEG-2000-DMG solution, 2.75 mL of polyoxyethylene hydrogenated castor oil solution and 2 mL of purified water and mix them evenly, add 10 mg of cyclosporine, and continue stirring at 40° C. until the cyclosporine is dissolved.

[0065] Example 5

[0066] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0067] (1) Accurately weigh polyoxyethylene lauryl alcohol ether (Brij 35), add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh MPEG-2000-DSG, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0068] (2) Take 2.5 mL of MPEG-2000-DSG solution, 2.5 mL of lauryl alcohol polyoxyethylene ether solution and 2 mL of purified water and mix them evenly, add 10 mg of cyclosporine, and continue stirring at 25° C. until the cyclosporine is dissolved.

[0069] Example 6

[0070] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0071] (1) Accurately weigh polysorbate 80, add pure water to dissolve it, and prepare a 20 mg / mL solution; accurately weigh polyethylene glycol 15-hydroxystearate, add pure water to dissolve it, and prepare a 20 mg / mL solution.

[0072] (2) Take 3 mL of polysorbate 80 solution and 5 mL of polyethylene glycol 15-hydroxystearate solution, mix them evenly, add 10 mg of cyclosporine, and continue stirring at 60° C. until the cyclosporine is dissolved.

[0073] Example 7

[0074] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0075] (1) Accurately weigh polyoxyethylene hydrogenated castor oil, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh MPEG-5000-DPPE, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0076] (2) Take 3 mL of MPEG-5000-DPPE solution and mix evenly with 5 mL of polyoxyethylene hydrogenated castor oil solution, add 10 mg of cyclosporine, and continue stirring at 60° C. until the cyclosporine is dissolved.

[0077] Example 8

[0078] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0079] (1) Accurately weigh poloxamer 188, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh polyethylene glycol 15-hydroxystearate, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0080] (2) Accurately weigh MPEG-2000-DSPE, add pure water to dissolve it, and prepare a 20 mg / mL solution; take 2.5 mL of MPEG-5000-DSPE solution, 2 mL of polyethylene glycol 15-hydroxystearate and 2.5 mL of poloxamer 188 solution, mix them evenly, add 15 mg of cyclosporine, and continue shaking at 25° C. until cyclosporine is dissolved.

[0081] Example 9

[0082] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, and the preparation method thereof is as follows:

[0083] (1) Accurately weigh polyoxyl 40 stearate, add pure water to dissolve, and prepare a 20 mg / mL solution; accurately weigh ALC-0159, add pure water to dissolve, and prepare a 20 mg / mL solution.

[0084] (2) Take 1 mL of ALC-0159 solution and 6 mL of polyoxyl 40 stearate solution, mix them evenly, add 5 mg of cyclosporine, and continue stirring at 25° C. until the cyclosporine is dissolved.

[0085] Example 10

[0086] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, the preparation method of which is different from that of embodiment 1 only in step (2), and the other conditions are the same as those of the embodiment: 2 mL of MPEG-2000-DSPE solution, 3 mL of polyoxyethylene hydrogenated castor oil solution and 2 mL of purified water are mixed evenly, 30 mg of cyclosporine is added, and stirring is continued at 60°C. The results show that after 10 hours, the solution is still turbid and a large number of drug particles are not dissolved. After filtering the solution through a 0.22 micron membrane, the concentration of cyclosporine is detected by HPLC, and the concentration is 1.721 mg / mL.

[0087] Embodiment 11

[0088] This embodiment provides an ophthalmic cyclosporine nano-micelle drug, the preparation method of which is different from that of embodiment 1 only in step (2), and the other conditions are the same as those of the embodiment: 0.4 mL of MPEG-2000-DSPE solution, 4.6 mL of polyoxyethylene hydrogenated castor oil solution and 2 mL of purified water are mixed evenly, 10 mg of cyclosporine is added, and stirring is continued at 60° C. The results show that some drug particles in the solution are not dissolved. After filtering the solution through a 0.22 μm membrane, the concentration of cyclosporine is detected by HPLC, and the concentration is 0.3914 mg / mL.

[0089] Comparative Example 1

[0090] The preparation method is different from that of Example 1 only in that the MPEG-2000-DSPE solution in step (2) is replaced by a polyoxyethylene hydrogenated castor oil solution:

[0091] (1) Accurately weigh polyoxyethylene hydrogenated castor oil and add pure water to dissolve it to prepare a 20 mg / mL solution.

[0092] (2) 5 mL of polyoxyethylene hydrogenated castor oil solution was mixed with 2 mL of purified water, 10 mg of cyclosporine was added, and stirring was continued at 60°C. The results showed that after 10 hours, the solution was still turbid, cyclosporine was not dissolved, and nanomicelles could not be formed.

[0093] Comparative Example 2

[0094] The preparation method is different from that of Example 3 only in that the MPEG-2000-DSPE solution in step (2) is replaced by a polysorbate 80 solution:

[0095] (1) Accurately weigh polysorbate 80 and dissolve it in pure water to prepare a 20 mg / mL solution.

[0096] (2) 5 mL of polysorbate 80 solution was mixed with 2 mL of purified water, and 10 mg of cyclosporine was added. The mixture was stirred continuously at 4°C. The results showed that after 10 hours, the solution was still turbid, and cyclosporine was not dissolved and could not form nanomicelles.

[0097] Comparative Example 3

[0098] The difference between the preparation method and Example 5 is that the MPEG-2000-DSG solution in step (2) is replaced by a lauryl alcohol polyoxyethylene ether solution:

[0099] (1) Accurately weigh polyoxyethylene lauryl alcohol ether (Brij 35), add pure water to dissolve, and prepare a 20 mg / mL solution.

[0100] (2) 5 mL of lauryl alcohol polyoxyethylene ether solution was mixed evenly with 2 mL of purified water, 10 mg of cyclosporine was added, and stirring was continued at 25°C. The results showed that after 10 hours, the solution was still turbid, cyclosporine was not dissolved, and nanomicelles could not be formed.

[0101] Test Example 1

[0102] In this test example, the products obtained in Examples 1-9 were characterized by particle size using a laser particle size analyzer. The results are shown in Table 1.

[0103] Table 1

[0104]

[0105]

[0106] It can be seen from the data in Table 1 that the ophthalmic cyclosporine nano-micelle drug of the present invention can be prepared by using a direct hydration method, and the system is colorless, clear and transparent with uniform particle size.

[0107] Application Example 1

[0108] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0109] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 30 mg of thickener PVP-K90 in 1 mL of pure water; mix the product of Example 1 with the above two solutions, and add pure water to reach a final volume of 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0110] Application Example 2

[0111] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0112] Dissolve 530 mg of disodium hydrogen phosphate (dihydrate), 470 mg of sodium dihydrogen phosphate (anhydrous), and 50 mg of sodium chloride in 10 mL of pure water, and take 1 mL for later use; dissolve 10 mg of thickener hydroxypropyl methylcellulose in 10 mL of pure water, and take 1 mL for later use; mix the product of Example 2 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0113] Application Example 3

[0114] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0115] Dissolve 795 mg of disodium hydrogen phosphate (dihydrate), 705 mg of sodium dihydrogen phosphate (anhydrous), and 75 mg of sodium chloride in 15 mL of pure water, and take 1 mL for later use; dissolve 100 mg of sodium hyaluronate, a thickener, in 15 mL of pure water, and take 1 mL for later use; mix the product of Example 3 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0116] Application Example 4

[0117] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0118] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 200 mg of thickener hydroxypropyl methylcellulose in 15 mL of pure water, and take 1 mL for later use; mix the product of Example 4 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0119] Application Example 5

[0120] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0121] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 30 mg of thickener PVP-K90 in 1 mL of pure water; mix the product of Example 5 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0122] Application Example 6

[0123] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0124] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 30 mg of thickener PVP-K90 in 1 mL of pure water; mix the product of Example 6 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0125] Application Example 7

[0126] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0127] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 200 mg of thickener hydroxypropyl methylcellulose in 15 mL of pure water, and take 1 mL for later use; mix the product of Example 7 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0128] Application Example 8

[0129] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0130] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 30 mg of thickener PVP-K90 in 1 mL of pure water; mix the product of Example 8 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0131] Application Example 9

[0132] This application example provides a cyclosporine eye drops, the preparation method of which is as follows:

[0133] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 1 mL for later use; dissolve 30 mg of thickener PVP-K90 in 1 mL of pure water; mix the product of Example 9 with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.

[0134] Test Example 2

[0135] In this test example, the products prepared in application examples 1-9 were placed at 35° C. for 30 days, and the cyclosporine content was measured before and after the placement using a high performance liquid chromatograph. The results are shown in Table 2.

[0136] Table 2

[0137] Group Before placement (%) After placement (%) Application Example 1 0.09482 0.09703 Application Example 2 0.19712 0.19717 Application Example 3 0.09564 0.09834 Application Example 4 0.09589 0.09692 Application Example 5 0.09664 0.09620 Application Example 6 0.09739 0.09588 Application Example 7 0.09926 0.09985 Application Example 8 0.14739 0.14961 Application Example 9 0.04678 0.04624

[0138] It can be seen from the data in Table 2 that the cyclosporine content in the ophthalmic cyclosporine nano-micelle drug and cyclosporine eye drops of the present invention does not change significantly after being placed at 35° C. for 30 days, and has good stability.

[0139] Test Example 3

[0140] This test example is used to conduct eye irritation test on the products made from Examples 1-9:

[0141] A total of 24 healthy rabbits were randomly divided into 8 groups, with 3 rabbits in each group. 50 μL of the test product was dripped into the left eye of each rabbit, and 50 μL of normal saline was dripped into the right eye, and the eyelids were gently closed for 10 seconds. The drug was administered 4 times a day for 7 consecutive days. The local reactions of the cornea, iris, and conjunctiva of the rabbits were observed before administration and 1, 2, 4, 24, 48, and 72 hours after the last administration every day, and the total score was calculated. The irritation score of normal saline was 0 points. Test scoring criteria and methods: See the table below.

[0142]

[0143] The result judgment criteria are shown in the following table:

[0144] Thrill Level Total score Criteria 1 0-3 points Non-irritating 2 4-8 points Mild irritation 3 9-12 points Moderate irritation 4 13-16 points Intensity of stimulation

[0145] The eye irritation test results of each group are shown in Table 3:

[0146] Table 3

[0147]

[0148]

[0149] It can be seen from the data in Table 3 that the ophthalmic cyclosporine nano-micelle drug and cyclosporine eye drops of the present invention have no obvious irritation to the eyes of rabbits and are safe and mild.

[0150] Test Example 4

[0151] This test case performs a pharmacokinetic test on the product prepared in Example 2:

[0152] A total of 60 healthy rabbits were randomly divided into 20 groups, with 3 rabbits in each group. 10 groups of experimental rabbits were dripped with 35 μL of the product prepared in Application Example 2 in both eyes, and the other 10 groups of experimental rabbits were dripped with a control product (0.05% cyclosporine eye drops II produced by Shenyang Xingqi Eye Medicine Co., Ltd.) )140μL. The experimental rabbits in groups 1-10 were killed at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 hours after administration, and the conjunctiva was taken. Immediately afterwards, the rabbits were enucleated, and the eyeballs were dissected to separate the cornea and sclera. After grinding and homogenizing each tissue, the cyclosporine content in the tissue was analyzed by high performance liquid chromatography-mass spectrometry. Pharmacokinetic parameters of cyclosporine in cornea, conjunctiva, and sclera C max and AUC (0-t) See Table 4. The changes in the concentration of cyclosporine in the cornea, conjunctiva and sclera over time are shown in Figure 1-Figure 3 In the figure, the X-axis is time (h) and the Y-axis is the cyclosporine drug concentration in the tissue (ng / g).

[0153] Table 4

[0154]

[0155]

[0156] From Table 4 and Figure 1-Figure 3 The data show that the cyclosporine nano-micelle drug and cyclosporine eye drops of the present invention significantly increase the cyclosporine concentration and exposure (AUC (0-t)), indicating that it may produce better results in actual clinical use.

[0157] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0158] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0159] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A cyclosporine nano-micelle drug for eye use, characterized in that: The ophthalmic cyclosporine nano-micelle drug is composed of a first solubilizing agent and a second solubilizing agent that form micelle particles, and cyclosporine loaded in the micelle particles; The first solubilizing agent is selected from any one or a combination of at least two of polyoxyethylene hydrogenated castor oil, polysorbate 80, polyoxyethylene lauryl ether, poloxamer 188, polyoxyl 40 stearate or tyloxapol; The second solubilizing agent is selected from polyethylene glycol 15-hydroxystearate or any one or a combination of at least two of the following structural compounds: In the above structural compound, R is independently selected from C9-C26 alkyl; R1 is selected from C1-C5 alkylene; R2 is independently selected from H, methyl or ethyl; M+ is selected from Na + , K + or NH4 + ; The molecular weight of the polyethylene glycol chain segments is independently 500-20000.

2. The ophthalmic cyclosporine nano-micelle drug according to claim 1, characterized in that: The second solubilizer is selected from any one of polyethylene glycol 15-hydroxystearate, mPEG-DSPE, mPEG-DPPE, ALC-0159, mPEG-DMG, and mPEG-DSG, or a combination of at least two thereof; in the above structural compounds, the molecular weight of the polyethylene glycol segments is independently 500-20000.

3. The ophthalmic cyclosporine nano-micelle drug according to claim 1 or 2, characterized in that: The ratio of the total mass of the first solubilizing agent and the second solubilizing agent to the mass of cyclosporine is not less than 4:1; Preferably, the mass ratio of the first solubilizing agent to the second solubilizing agent is not higher than 10:

1.

4. The ophthalmic cyclosporine nano-micelle drug according to any one of claims 1 to 3, characterized in that: The particle size of the ophthalmic cyclosporine nano-micelle drug is 5-100 nm.

5. The method for preparing the ophthalmic cyclosporine nano-micelle drug according to any one of claims 1 to 4, characterized in that: The preparation method comprises: Cyclosporine is mixed with the first solubilizing agent, the second solubilizing agent and water to dissolve the cyclosporine, thereby obtaining the ophthalmic cyclosporine nano-micelle drug.

6. The preparation method according to claim 5, characterized in that: The dissolving is carried out at 0-70°C; Preferably, the dissolution is carried out by any one or at least two of the following methods: (1) stirring; (2) shaking; (3) ultrasonic treatment; Preferably, the final concentration of cyclosporine in the mixed system is 0.2-10 mg / mL; Preferably, the final concentration of the first solubilizing agent in the mixed system is 0.01-20 mg / mL; Preferably, the final concentration of the second solubilizer in the mixed system is 2-30 mg / mL; Preferably, the ratio of the total mass of the first solubilizer and the second solubilizer to the mass of cyclosporine is not less than 4:1; Preferably, the mass ratio of the first solubilizing agent to the second solubilizing agent is not higher than 10:

1.

7. Use of the ophthalmic cyclosporine nano-micelle drug according to any one of claims 1 to 4 in the preparation of an ophthalmic cyclosporine preparation.

8. A cyclosporine eye drop, characterized in that: The raw materials for preparing the cyclosporine eye drops include the ophthalmic cyclosporine nano-micelle drug according to any one of claims 1 to 4.

9. The cyclosporine eye drops according to claim 8, characterized in that The raw materials for preparing the cyclosporine eye drops also include any one of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative, or a combination of at least two of them.

10. The method for preparing cyclosporine eye drops according to claim 8 or 9, characterized in that: The preparation method comprises: The ophthalmic cyclosporine nano-micelle drug is mixed and dissolved in water with any one of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative, or a combination of at least two of the two, to obtain; Preferably, after the mixed dissolution, the solution is filtered through a 0.22 micron filter to remove insoluble particles.

Citation Information

Patent Citations

  • Macrogol 15 hydroxystearate formulations

    CN103764120A

  • Composition for eyes and having improved drying protection and retention

    CN110090294A

  • Pharmaceutical composition for injection

    CN111214440A

  • Ophthalmic composition and application thereof in preparation of medicine for xerophthalmia

    CN111905094A

  • In-situ gel containing cyclosporin micelle as sustained-release ophthalmic drug delivery system

    CN112516084A

Cited By

  • Ophthalmic cyclosporine nano-micelle drug, preparation method therefor, and use thereof

    WO2025108351A1